Drugs / RV-NYESO TCR PBMC
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03506802 | Jul 2018 → Jun 2019 | plasma cell myeloma | Jonsson Comprehensive Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03240861 | Jul 2017 → Oct 2023 | high grade malignant neoplasm, sarcoma | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RV-NYESO TCR PBMC | “LV-NYESO TCR /sr39TK PBSC and RV-NYESO TCR PBMC given IV” NCT03506802 ↗1“patients receive RV-NYESO TCR PBMC IV on day 1” NCT03240861 ↗ |
| Action | Deplete | “redirected to attack and kill the cancer cells” NCT03506802 ↗ |
| Modality | Cell therapy | “TCR transduced autologous PBMC and CD34+ PBSC” NCT03506802 ↗ |
| Route | Intravenous | “patients receive RV-NYESO TCR PBMC IV on day 1” NCT03240861 ↗ |